Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.57 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.46 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973337 | 0.88 | EGLN1 (0.46) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL5287623 | 0.85 | EGLN1 (0.43) | EGLN1EGLN2 | |
| SCHEMBL1971895 | 0.80 | PTGS1 (0.39) | — | |
| SCHEMBL967008 | 0.80 | EGLN1 (0.56) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL2881449 | 0.77 | EGLN1 (0.56) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL969590 | 0.77 | EGLN1 (0.58) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL968819 | 0.75 | EGLN1 (0.58) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL2775171 | 0.73 | EGLN1 (0.56) | EGLN1EGLN2EGLN3VEGFAFLT1 | |
| SCHEMBL1269046 | 0.73 | EGLN1 (1.00) | EGLN1EGLN2EGLN3 | |
| SCHEMBL19917251 | 0.72 | EGLN1 (0.58) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | claimed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | claimed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | claimed |
| EP-4142721-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | Bioage Labs, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. | 2021-11-18 | — | — | US | disclosed |
| WO-2021222424-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | BioAge Labs, Inc. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9775902-B2 | Compounds and methods for treatment of stroke | FIBROGEN, INC (US) | 2017-10-03 | — | — | US | disclosed |
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8530404-B2 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | FIBROGEN, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | FIBROGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007097929-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF STROKE | FIBROGEN, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | FIBROGEN, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060276477-A1 | Treatment method for anemia | FIBROGEN, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885EGLN3 4/4885 |
| US-20210353612-A1 | HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR TREATING AGING-RELATED CONDITIONS | HIF1AN, HIF1A, P4HA1 | EGLN1 11/4885EGLN2 5/4885EGLN3 4/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885EGLN3 4/4885 |
| US-20060276477-A1 | Treatment method for anemia | THPO, EPOR, MPL | EGLN1 85/4885EGLN2 8/4885EGLN3 12/4885 |
| US-20070259960-A1 | Compounds and methods for treatment of stroke | PLAT, SERPINE1, PLG | EGLN1 740/4885EGLN2 415/4885EGLN3 494/4885 |
| US-20070004627-A1 | Compounds and methods for treatment of cancer | TP53, MKI67, HDGF | EGLN1 98/4885EGLN2 39/4885EGLN3 36/4885 |
| US-20070293575-A1 | Compounds and methods for treatment of cancer-related anemia | EPOR, THPO, TFRC | EGLN1 21/4885EGLN2 11/4885EGLN3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.